Population Pharmacokinetics and Exposure-Response with Durvalumab Plus Platinum-Etoposide in ES-SCLC: Results from CASPIAN

被引：0
|
作者：
Zheng, Y. [1 ]
Jin, D. [1 ]
Guan, Y. [1 ]
Ozguroglu, M. [2 ]
Trukhin, D. [3 ]
Poltoratskiy, A. [4 ]
Chen, Y. [5 ]
Havel, L. [6 ]
Hochmair, M. [7 ]
Paz-Ares, L. [8 ,9 ]
Jiang, H. [10 ]
Armstrong, J. [11 ]
Chen, C. [1 ]
Liu, Y. H. [10 ]
Roskos, L. [1 ]
机构：
[1] Astrazeneca, San Francisco, CA USA
[2] Istanbul Univ Cerrahpasa, Cerrahpasa Sch Med, Istanbul, Turkey
[3] Odessa Reg Oncol Dispensary, Odessa, Ukraine
[4] Petrov Res Inst Oncol, St Petersburg, Russia
[5] Canc & Hematol Ctr Western Michigan, Grand Rapids, MI USA
[6] Charles Univ Prague, Fac Med 1, Thomayer Hosp, Prague, Czech Republic
[7] Krankenhaus Nord, Karl Landsteiner Inst Lung Res & Pulm Oncol, Vienna, Austria
[8] Univ Complutense, Hosp Univ 12 Octubre, H120 Cnio Lung Canc Unit, Madrid, Spain
[9] Ciberonc, Madrid, Spain
[10] Astrazeneca, Gaithersburg, MD USA
[11] Astrazeneca, Cambridge, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
CASPIAN; population pharmacokinetics; Durvalumab;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P48.21
引用
收藏
页码：S508 / S508
页数：1
相关论文
共 50 条
  • [1] First-Line Durvalumab plus Platinum-Etoposide in ES-SCLC: Exploratory Analyses Based on Extent of Disease in CASPIAN
    Reinmuth, N.
    Garassino, M. C.
    Trukhin, D.
    Hochmair, M. J.
    Ozguroglu, M.
    Havel, L.
    Goldman, J.
    Chen, Y.
    Losonczy, G.
    Spinnato, F.
    Conev, N.
    Bar, J.
    Broadhurst, H.
    Byrne, N.
    Jiang, H.
    Paz-Ares, L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S500 - S500
  • [2] Durvalumab ± Tremelimumab plus Platinum-Etoposide in 1L ES-SCLC: Exploratory Analysis of HLA Genotype and Survival in CASPIAN
    Garassino, M. C.
    Shrestha, Y.
    Xie, M.
    Lai, Z.
    Spencer, S.
    Dalvi, T.
    Paz-Ares, L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S939 - S939
  • [3] Durvalumab ± tremelimumab plus platinum-etoposide in 1L ES-SCLC: exploratory analysis of HLA genotype and survival in CASPIAN
    Alt, J.
    Garassino, M. C.
    Shrestha, Y.
    Xie, M.
    Lai, Z.
    Spencer, S.
    Dalvi, T.
    Paz-Ares, L.
    Reinmuth, N.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 54 - 55
  • [4] Durvalumab ± tremelimumab plus platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study.
    Paz-Ares, Luis G.
    Dvorkin, Mikhail
    Chen, Yuanbin
    Reinmuth, Niels
    Hotta, Katsuyuki
    Trukhin, Dmytro
    Statsenko, Galina
    Hochmair, Maximilian
    Ozguroglu, Mustafa
    Ji, Jun Ho
    Voitko, Oleksandr
    Poltoratskiy, Artem
    Verderame, Francesco
    Havel, Libor
    Bondarenko, Igor
    Armstrong, Jon
    Byrne, Natalie
    Jiang, Haiyi
    Goldman, Jonathan Wade
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] Durvalumab ± tremelimumab plus platinum-etoposide in first-line (1L) extensive-stage SCLC (ES-SCLC): Results from the phase 3 CASPIAN study
    Grohe, C.
    Paz-Ares, L. G.
    Dvorkin, M.
    Chen, Y.
    Hotta, K.
    Trukhin, D.
    Statsenko, G.
    Hochmair, M. J.
    Ozguroglu, M.
    Ji, J. H.
    Voitko, O.
    Poltoratskiy, A.
    Verderame, F.
    Havel, L.
    Bondarenko, I.
    Armstrong, J.
    Byrne, N.
    Jiang, H.
    Goldman, J. W.
    Reinmuth, N.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 149 - 149
  • [6] PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN
    Paz-Ares, L.
    Goldman, J. W.
    Garassino, M. C.
    Dvorkin, M.
    Trukhin, D.
    Statsenko, G.
    Hotta, K.
    Ji, J. H.
    Hochmair, M. J.
    Voitko, O.
    Havel, L.
    Poltoratskiy, A.
    Losonczy, G.
    Reinmuth, N.
    Shrestha, Y.
    Patel, N.
    Mann, H.
    Jiang, H.
    Ozguroglu, M.
    Chen, Y.
    ANNALS OF ONCOLOGY, 2019, 30 : 928 - +
  • [7] First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC: Safety, pharmacokinetics (PK) and immunogenicity in CASPIAN
    Ozguroglu, M.
    Goldman, J. W.
    Reinmuth, N.
    Chen, Y.
    Dvorkin, M.
    Trukhin, D.
    Statsenko, G.
    Hotta, K.
    Ji, J. H.
    Hochmair, M. J.
    Voitko, O.
    Havel, L.
    Poltoratskiy, A.
    Losonczy, G.
    Verderame, F.
    Thomas, M.
    Zheng, Y.
    Lloyd, A.
    Jiang, H.
    Paz-Ares, L.
    ANNALS OF ONCOLOGY, 2019, 30 : 66 - 66
  • [8] Assessment of the Efficacy and Safety of Durvalumab Associated with Platinum-Etoposide in Previously Untreated ES-SCLC in Brazil
    Lopes, D.
    Zukin, M.
    Calabrich, A.
    Cordeiro de Lima, V.
    Corassa, M.
    Gossling, G.
    Gomes de Jesus, R.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S376 - S376
  • [9] A Study of the Best Reduction in Target Lesion Size and Treatment Duration in the Durvalumab plus Platinum-Etoposide Regimen for ES-SCLC
    Watanabe, K.
    Uehara, Y.
    Hosomi, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S546 - S546
  • [10] Durvalumab(D) ± tremelimumab(T) plus platinum-etoposide(EP) in 1L ES-SCLC: Characterization of long-term benefit in CASPIAN
    Saito, Haruhiro
    Goldman, Jonathan W.
    Garassino, Marina Chiara
    Chen, Yuanbin
    Reinmuth, Niels
    Hotta, Katsuyuki
    Poltoratskiy, Artem
    Trukhin, Dmytro
    Hochmair, Maximilian J.
    Ozguroglu, Mustafa
    Ji, Jun Ho
    Statsenko, Galina
    Voitko, Oleksandr
    Conev, Nikolay V.
    Bondarenko, Igor
    Spencer, Stuart
    Xie, Mingchao
    Jones, Stephanie
    Franks, April
    Shrestha, Yashaswi
    Paz-Ares, Luis
    ANNALS OF ONCOLOGY, 2021, 32 : S289 - S289
12345